A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation (The ReInspire Study)

Clinical trial NCT06789913 · RECRUITING

Trial details

NCT number: NCT06789913
Sponsor: Relay Therapeutics, Inc.
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

PIK3CA-Related Overgrowth Spectrum (PROS)Lymphatic Malformations Vascular Malformations PIK3CA Mutation CLOVES Syndrome Klippel Trenaunay Syndrome Megalencephaly-capillary Malformation Polymicrogyria Syndrome (MCAP)Vascular Anomalies

Start date: 2025-06-13
Primary completion: 2031-07-01
Enrollment: 277

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.